Price Vision Group | Indianapolis, IN
Status and phase
Conditions
Treatments
About
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Other inclusion/exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
131 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Clinical Operations Representative
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal